OP0139 ASSESSMENT OF ULTRASOUND DEFINITIONS AND A SCORING SYSTEM FOR SALIVARY GLAND DISEASE IN PRIMARY SJÖGREN'S SYNDROME: AN OMERACT PATIENT RELIABILITY EXERCISE. (June 2019)
- Record Type:
- Journal Article
- Title:
- OP0139 ASSESSMENT OF ULTRASOUND DEFINITIONS AND A SCORING SYSTEM FOR SALIVARY GLAND DISEASE IN PRIMARY SJÖGREN'S SYNDROME: AN OMERACT PATIENT RELIABILITY EXERCISE. (June 2019)
- Main Title:
- OP0139 ASSESSMENT OF ULTRASOUND DEFINITIONS AND A SCORING SYSTEM FOR SALIVARY GLAND DISEASE IN PRIMARY SJÖGREN'S SYNDROME: AN OMERACT PATIENT RELIABILITY EXERCISE
- Authors:
- Finzel, Stephanie
Jousse-Joulin, Sandrine
Iagnocco, Annamaria
Naredo, Esperanza
Hocevar, Alojzija
Ohrndorf, Sarah
Hanova, Petra
D'agostino, Maria-Antonietta
Costantino, Felicie
Terslev, Lene
Keen, Helen
Bruyn, George - Abstract:
- Abstract : Background: Salivary gland ultrasound (SGUS) may have the potential of facilitating diagnosis and therapy monitoring of salivary gland disease in patients with primary Sjögren's syndrome (pSS). The aim of the Outcome Measures in Rheumatology Clinical Trials (OMERACT) US subgroup on SG is to validate US as an outcome measurement instrument in pSS. Following the OMERACT US stepwise validation approach, preliminary consensus definitions for elementary lesions based on a systematic literature review were developed and subsequently a scoring system has been agreed upon and tested through a web-based Delphi exercise. Objectives: To assess the reliability of consensus based SGUS scoring system in patients with SS. Methods: Nine sonographers conducted an US reliability exercise of the parotid and submandibular glands (PG, SMG) of 9 patients with primary and secondary SS in 3 rounds. A 4-grade semi-quantitative scoring was applied in B-mode for structural lesions as follows: Grade 0: normal, grade 1: mild inhomogeneity without anechoic or hypoechoic areas, grade 2: moderate inhomogeneity with focal anechoic or hypoechoic areas, grade 3: severe; diffuse inhomogeneity with an-/hypoechoic areas occupying all the surface of the gland. Next, presence or absence of typical pSS-lesions was scored in binary fashion. Intrareader and interreader reliability were computed by Cohen and Light kappa. Weighted k coefficients with absolute weighting were calculated for B-modeAbstract : Background: Salivary gland ultrasound (SGUS) may have the potential of facilitating diagnosis and therapy monitoring of salivary gland disease in patients with primary Sjögren's syndrome (pSS). The aim of the Outcome Measures in Rheumatology Clinical Trials (OMERACT) US subgroup on SG is to validate US as an outcome measurement instrument in pSS. Following the OMERACT US stepwise validation approach, preliminary consensus definitions for elementary lesions based on a systematic literature review were developed and subsequently a scoring system has been agreed upon and tested through a web-based Delphi exercise. Objectives: To assess the reliability of consensus based SGUS scoring system in patients with SS. Methods: Nine sonographers conducted an US reliability exercise of the parotid and submandibular glands (PG, SMG) of 9 patients with primary and secondary SS in 3 rounds. A 4-grade semi-quantitative scoring was applied in B-mode for structural lesions as follows: Grade 0: normal, grade 1: mild inhomogeneity without anechoic or hypoechoic areas, grade 2: moderate inhomogeneity with focal anechoic or hypoechoic areas, grade 3: severe; diffuse inhomogeneity with an-/hypoechoic areas occupying all the surface of the gland. Next, presence or absence of typical pSS-lesions was scored in binary fashion. Intrareader and interreader reliability were computed by Cohen and Light kappa. Weighted k coefficients with absolute weighting were calculated for B-mode abnormalities. Results: Light weighted kappa for grading and diagnostic evaluation for intra- and inter-reader reliability was moderate to excellent (see Table for details). Conclusion: The developed US definitions and the scoring system for salivary gland lesions in pSS showed a good to excellent reliability in patients with SS. Next step is to apply the scoring system in clinical trials. Disclosure of Interests: Stephanie Finzel: None declared, Sandrine Jousse-Joulin: None declared, Annamaria Iagnocco: None declared, Esperanza Naredo Consultant for: Abbvie, Speakers bureau: AbbVie, Roche, Bristol-Myers Squibb, Pfizer, UCB, Lilly, Novartis, Janssen, and Celgene GmbH, ALOJZIJA HOCEVAR: None declared, Sarah Ohrndorf: None declared, Petra Hanova: None declared, Maria-Antonietta d'Agostino: None declared, Felicie Costantino: None declared, Lene Terslev Speakers bureau: Speakers fee from : Roche, Novartis, Pfizer, MSD, BMS, Celgene, Helen Keen: None declared, George Bruyn : None declared … (more)
- Is Part Of:
- Annals of the rheumatic diseases. Volume 78(2019)Supplement 2
- Journal:
- Annals of the rheumatic diseases
- Issue:
- Volume 78(2019)Supplement 2
- Issue Display:
- Volume 78, Issue 2 (2019)
- Year:
- 2019
- Volume:
- 78
- Issue:
- 2
- Issue Sort Value:
- 2019-0078-0002-0000
- Page Start:
- 145
- Page End:
- 145
- Publication Date:
- 2019-06
- Subjects:
- Rheumatism -- Periodicals
616.723005 - Journal URLs:
- http://ard.bmjjournals.com/ ↗
http://www.pubmedcentral.nih.gov/tocrender.fcgi?journal=149&action=archive ↗
http://www.bmj.com/archive ↗
http://gateway.ovid.com/server3/ovidweb.cgi?T=JS&MODE=ovid&D=ovft&PAGE=titles&SEARCH=annals+of+the+rheumatic+diseases.tj&NEWS=N ↗ - DOI:
- 10.1136/annrheumdis-2019-eular.7320 ↗
- Languages:
- English
- ISSNs:
- 0003-4967
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 20116.xml